Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects

NCT02798406 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
49
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

DNAtrix, Inc.

Collaborators